The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BioXCel therapeutics
Research Funding - BioXCell
Patents, Royalties, Other Intellectual Property - BioXCell
Travel, Accommodations, Expenses - BioXCell
Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.
 
Luca Rastelli
Employment - BioXCel therapeutics
Stock and Other Ownership Interests - BioXCel therapeutics
Research Funding - BioXCel therapeutics
Patents, Royalties, Other Intellectual Property - bioxcel therapeutics
Travel, Accommodations, Expenses - BioXCel therapeutics
 
Snigdha Gupta
Employment - BioXCel therapeutics
Research Funding - BioXCell
Patents, Royalties, Other Intellectual Property - BioXCell
Travel, Accommodations, Expenses - BioXCell
 
Zeenia Jagga
No Relationships to Disclose
 
Deborah H. Charych
Employment - Nektar
Stock and Other Ownership Interests - Nektar
Research Funding - Nektar
Patents, Royalties, Other Intellectual Property - Nektar
 
Jonathan Zalevsky
Employment - Nektar
Stock and Other Ownership Interests - Nektar
Research Funding - Nektar
Patents, Royalties, Other Intellectual Property - Nektar